Data from Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients

• DOI: 10.1158/1078-0432.c.6529070.v1
• Publication Date: 2023-04-01T06:20:52Z
• Authors: Daniela Osti; Massimiliano Del ...; Germana Rappa; Mark Santos; Vittoria Matafora; Cristina Richichi; Stefania Faletti; Galina V. Beznous...; Alexandre Mironov; Angela Bachi; Lorenzo Fornasari; Daniele Bongetta; Paolo Gaetani; Francesco DiMeco; Aurelio Lorico; Giuliana Pelicci
• Keywords: Extracellular vesicles; Extracellular Vesicles; Nanoparticle tracking analysis; Blood plasma

<div>AbstractPurpose:<p>Glioblastoma (GBM) is the most common primary brain tumor. The identification of blood biomarkers reflecting tumor status represents a major unmet need for optimal clinical management patients with GBM. Their high number in body fluids, their stability, and presence many tumor-associated proteins RNAs make extracellular vesicles potentially biomarkers. Here, we investigated potential role plasma from GBM diagnosis follow-up after treatment as prognostic tool.</p>Experimental Design:<p>Plasma healthy controls (<i>n</i> = 33), 43), different central nervous system malignancies 25) were collected. Extracellular isolated by ultracentrifugation characterized terms morphology transmission electron microscopy, concentration, size nanoparticle tracking analysis, protein composition mass spectrometry. An orthotopic mouse model human confirmed vesicle quantifications. Associations between concentration clinicopathologic features analyzed. All statistical tests two-sided.</p>Results:<p>GBM releases heterogeneous detectable plasma. Plasma was higher compared (<i>P</i> < 0.001), metastases extra-axial tumors 0.001). After surgery, significant drop measured also increased GBM-bearing mice Proteomic profiling revealed GBM-distinctive signature.</p>Conclusions:<p>Higher levels may assist diagnosis: reduction resection, rise at recurrence, cargo might provide indications about tumor, therapy response, monitoring.</p></div>